324 related articles for article (PubMed ID: 26470766)
1. Efficacy of Adalimumab in Korean Patients with Crohn's Disease.
Sohn IW; Kim ST; Kim B; Lee HJ; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Gut Liver; 2016 Mar; 10(2):255-61. PubMed ID: 26470766
[TBL] [Abstract][Full Text] [Related]
2. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab induces deep remission in patients with Crohn's disease.
Colombel JF; Rutgeerts PJ; Sandborn WJ; Yang M; Camez A; Pollack PF; Thakkar RB; Robinson AM; Chen N; Mulani PM; Chao J
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.
Orlando A; Renna S; Mocciaro F; Cappello M; Di Mitri R; Randazzo C; Cottone M
Inflamm Bowel Dis; 2012 May; 18(5):826-31. PubMed ID: 21837774
[TBL] [Abstract][Full Text] [Related]
8. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
9. Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease.
Miyoshi J; Hisamatsu T; Matsuoka K; Naganuma M; Maruyama Y; Yoneno K; Mori K; Kiyohara H; Nanki K; Okamoto S; Yajima T; Iwao Y; Ogata H; Hibi T; Kanai T
Digestion; 2014; 90(2):130-6. PubMed ID: 25323803
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents.
Herrera-deGuise C; Casellas F; Robles V; Navarro E; Borruel N
J Gastroenterol Hepatol; 2015 Feb; 30(2):286-91. PubMed ID: 25302652
[TBL] [Abstract][Full Text] [Related]
11. [Adalimumab as induction therapy for Crohn's disease - one center study].
Gonciarz M; Mularczyk A; Szkudłapski D; Piątek I; Kopała M
Pol Merkur Lekarski; 2016 Nov; 41(245):216-220. PubMed ID: 27883347
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.
Takeshima F; Yoshikawa D; Higashi S; Morisaki T; Oda H; Ikeda M; Machida H; Matsushima K; Minami H; Akazawa Y; Yamaguchi N; Ohnita K; Isomoto H; Ueno M; Nakao K
BMC Gastroenterol; 2016 Jul; 16(1):82. PubMed ID: 27472988
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease.
Taxonera C; Barreiro-de-Acosta M; Bastida G; Martinez-Gonzalez J; Merino O; García-Sánchez V; Gisbert JP; Marín-Jiménez I; López-Serrano P; Gómez-García M; Iglesias E; Lopez-Sanroman A; Chaparro M; Saro C; Bermejo F; Pérez-Carazo L; Plaza R; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
J Crohns Colitis; 2016 Jun; 10(6):657-62. PubMed ID: 26786982
[TBL] [Abstract][Full Text] [Related]
14. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
16. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice.
Echarri A; Ollero V; Barreiro-de Acosta M; Fernández-Villaverde A; Hernández V; Lorenzo A; Pereira S; Carpio D; Castro J;
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):430-5. PubMed ID: 25874517
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
[TBL] [Abstract][Full Text] [Related]
19. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.
Panaccione R; Löfberg R; Rutgeerts P; Sandborn WJ; Schreiber S; Berg S; Maa JF; Petersson J; Robinson AM; Colombel JF
J Crohns Colitis; 2019 May; 13(6):725-734. PubMed ID: 30753371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
